Current Report Filing (8-k)
October 24 2017 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported) October 24, 2017
PSYCHEMEDICS CORPORATION
(Exact Name of Registrant As Specified In
Its Charter)
|
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
1-13738
(Commission File Number)
|
|
58-1701987
(I.R.S. Employer Identification No.)
|
|
|
|
125 Nagog Park, Acton, Massachusetts
|
|
01720
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(978) 206-8220
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instructions A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On October 24, 2017, Psychemedics Corporation issued a press
release announcing preliminary results for the Third Quarter of 2017. A copy of the press release is attached hereto as Exhibit
99.1 and incorporated by reference herein.
Limitation on Incorporation by Reference.
The
information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless
of any general incorporation language in such filing.
Cautionary Note Regarding Forward-Looking Statements.
Except for historical information contained in the press release attached as an exhibit hereto, the press release contains
forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from
those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking
statements.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 24,
2017
|
PSYCHEMEDICS CORPORATION
|
|
|
|
|
|
By:
|
/s/ Neil Lerner
|
|
|
|
Neil Lerner
|
|
|
|
Vice President, Finance
|
|
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From Apr 2023 to Apr 2024